Vor Biopharma Inc.

VOR • Biotechnology

$25.05

— 0.00 (0.00%)

ResultadosÚltimo reporte: 30 jun 2026

PERFIL DE MAYOR RIESGOPrecauciónConfianza: 70%

Perfil cuantitativo — no constituye una recomendación de inversión.

Perfil cuantitativo — no constituye una recomendación de inversión.Metodología

Tesis del análisis: Conviene actuar con cautela. Los ratios recientes muestran debilidades que pueden limitar el retorno si los fundamentales no mejoran.

Capitalización

$1.36B

Crecimiento

—

Flujo de caja

0/5

Tendencia

Negative

Evidencia

Liquidez saludable · 18.2Rentabilidad débil

Datos financieros hasta: 30 jun 2026, 12:00 a.m. UTCÚltima actualización de earnings: 30 jun 2026, 12:00 a.m. UTCÚltima actualización del perfil: 13 ago 2026, 12:09 p.m. UTC

Resumen de la compañía

Valoración, calidad, fortaleza financiera, momentum y datos de analistas.

Price$25.05

Change0.00%

Shares Out54.30M

Market Cap$1.36B

Enterprise Value$897.07M

52W Range6.50 - 50.20

Beta1.72

P/E2.17

P/B-6.79

P/FCF-9.64

EV/EBITDA-0.96

EV/FCF-6.36

Price$25.05

Change0.00%

Shares Out54.30M

Market Cap$1.36B

Enterprise Value$897.07M

52W Range6.50 - 50.20

Beta1.72

P/E2.17

P/B-6.79

P/FCF-9.64

EV/EBITDA-0.96

EV/FCF-6.36

Earnings Yield46.15%

FCF Yield-10.37%

Dividend Yield0.00%

Gross Margin0.00%

Oper. Margin0.00%

Profit Margin0.00%

Debt/Eq-0.02

Current Ratio18.20

Quick Ratio18.20

Target$29.00

Target Upside15.77%

Target Median$29.00

Target Range27.00 - 31.00

Volume975.43K

Avg Volume1.17M

EPS Surprise0.02

ADN de inversión

Qué tan fuerte luce esta compañía para inversionistas de largo plazo

de 100

Calidad del negocio

Márgenes, ventaja competitiva, retornos

22/100

Fortaleza financiera

Deuda, caja, estabilidad

70/100

Potencial de crecimiento

Ingresos y expansión

50/100

Atractivo del precio

Barata o cara hoy

95/100

Por qué este puntaje▼

Liquidez saludable · 18.2Rentabilidad débil

Analyst view

Analyst sentiment and price target

VOR

Analyst sentiment

Based on 13 analyst votes · 2026-09-05

88/100

Bullish

Hold

Bearish

Precio objetivo

2026-08-13

Bajo

$27.00

Promedio

$29.00

Mediana

$29.00

Alto

$31.00

Resumen de la compañía

IPO: 2/5/2021

Industria: Biotechnology

P/B i: -6.79

Deuda / Patrimonio i: -0.02

Margen operativo: 0.00%

Margen neto: 0.00%

ROE i: -

ROIC: -

Salud financiera

Puntaje14 / 20

Deuda / Patrimonio: -0.02

Ratio corriente: 18.20

Ratio rápido: 18.20

Estado: Good

Transacciones internas

Actividad reciente de ejecutivos e insiders

⚠ 7 venta interna de alto volumens detectadas

RA CAPITAL MANAGEMENT, L.P.

Transacción: 07/16/2026

VENTA

Cambio

-213

Precio

$19.75

Presentación

07/21/2026

Tipo

VENTA

RA CAPITAL MANAGEMENT, L.P.

Transacción: 07/16/2026

VENTA

Cambio

-2,100,000

Precio

$0.00

Presentación

07/21/2026

Tipo

VENTA

ZACCARDELLI DAVID

Transacción: 07/07/2026

COMPRA

Cambio

+42,658

Precio

$20.10

Presentación

07/09/2026

Tipo

COMPRA

Insider	Tipo	Cambio	Precio	Transacción	Presentación
RA CAPITAL MANAGEMENT, L.P.	VENTA	-213	$19.75	07/16/2026	07/21/2026
RA CAPITAL MANAGEMENT, L.P.	VENTA	-2,100,000	$0.00	07/16/2026	07/21/2026
ZACCARDELLI DAVID	COMPRA	+42,658	$20.10	07/07/2026	07/09/2026
ZACCARDELLI DAVID	OTRO	0	Not reported	07/07/2026	07/09/2026
Levin Andrew David	COMPRA	+57,162	$14.09	06/11/2026	06/12/2026
Beckman Daniella	COMPRA	+53,283	$14.09	06/11/2026	06/12/2026
Cumbo Alexander	COMPRA	+56,345	$14.09	06/11/2026	06/12/2026
Kalir Erez	COMPRA	+57,162	$14.09	06/11/2026	06/12/2026
Joustra Wouter	COMPRA	+57,162	$14.09	06/11/2026	06/12/2026
Namouni Fouad	COMPRA	+56,549	$14.09	06/11/2026	06/12/2026
Detheux Michel	COMPRA	+57,162	$14.09	06/11/2026	06/12/2026
RA CAPITAL MANAGEMENT, L.P.	COMPRA	+57,162	$14.09	06/11/2026	06/12/2026
RA CAPITAL MANAGEMENT, L.P.	VENTA	-165,150	$15.77	04/22/2026	04/24/2026
RA CAPITAL MANAGEMENT, L.P.	VENTA	-171,963	$15.77	04/20/2026	04/21/2026
RA CAPITAL MANAGEMENT, L.P.	VENTA	-458,411	$16.28	04/17/2026	04/21/2026
RA CAPITAL MANAGEMENT, L.P.	VENTA	-53,644	$16.01	04/15/2026	04/15/2026
RA CAPITAL MANAGEMENT, L.P.	VENTA	-153,735	$15.97	04/14/2026	04/15/2026
RA CAPITAL MANAGEMENT, L.P.	VENTA	-530,610	$16.15	04/13/2026	04/15/2026
RA CAPITAL MANAGEMENT, L.P.	VENTA	-828	$15.75	04/10/2026	04/10/2026
RA CAPITAL MANAGEMENT, L.P.	VENTA	-135,201	$16.59	04/09/2026	04/10/2026

Sobre la compañía

Vor Biopharma Inc.

Vor Biopharma, Inc. is a clinical-stage biotechnology firm dedicated to developing innovative engineered hematopoietic stem cell (eHSC) therapies for individuals battling cancer. Its lead product candidate, VOR33, is an eHSC therapy currently undergoing Phase 1/2 clinical trials. VOR33 is designed to target acute myeloid leukemia (AML) and various other hematological malignancies. A key feature of VOR33's eHSCs is their engineered absence of the CD33 protein, which is commonly found on AML blood cancer cells. The company's eHSC platform is intended to enable a range of targeted blood cancer treatments, including CAR-T cell therapies, bispecific antibodies, and antibody-drug conjugates. Vor Biopharma has established a partnership with Akron BioProducts for the development and manufacturing of cGMP nucleases. Established in 2015, the company's headquarters are located in Cambridge, Massachusetts.

Fuente - Link

Competidores

ACTU ALEC ANIX APLT FATE FBRX MCRB NKTX PEPG SPRO

Tamaño = capitalización · color = línea del gráfico

Rendimiento de peers · 1A

Top performers + empresa seleccionada

Ultimas Noticias

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, on September 1, 2026, the Compensation Committee of the Board of Directors granted stock options to purchase an aggregate of 83,600 shares of Vor Bio's common stock and restricted stock units (“RSUs”) representing the right to receive an aggregate of 17,900 shares of Vor Bio's common stock to 6 newly hired employees. The foregoing stock options and RSUs were granted as material inducements to employment with Vor Bio in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted under the Vor Biopharma Inc. 2023 Inducement Plan (the “Inducement Plan”).

GlobeNewsWire

Bank of America Corp DE Has $2.01 Million Stock Holdings in Vor Biopharma Inc. $VOR

Bank of America Corp DE increased its position in Vor Biopharma Inc. (NASDAQ: VOR) by 28,408.1% during the first quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 112,892 shares of the company's stock after purchasing an additional 112,496 shares during the quarter. Bank of

Defense World

Vor Bio To Participate in Upcoming September Conferences

BOSTON, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that management will participate in the following investor conferences: Wells Fargo 21st Annual Healthcare Conference Forum: Fireside Chat and 1x1 Meetings Date: Tuesday, September 8th Presentation Time: 8:00AM ET Citi's 2026 Biopharma Back to School Conference Forum: Fireside Chat and 1x1 Meetings Date: Wednesday, September 9th Presentation Time: 11:20AM ET Morgan Stanley 24th Annual Global Healthcare Conference Forum: 1x1 Meetings Date: Monday, September 14th Baird's 2026 Global Healthcare Conference Forum: Presentation and 1x1 Meetings Date: Tuesday, September 15th Presentation Time: 9:05AM ET Stifel's 2026 Virtual Immunology and Inflammation Forum Forum: Presentation and 1x1 Meetings Date: Wednesday, September 23rd Presentation Time: 11:30AM ET A live webcast of the presentation may be accessed on the Investors section of the Vor website at ir.vorbio.com.

GlobeNewsWire

Vor Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Enrollment on track for Phase 3 UPSTREAM MG trial of telitacicept in generalized myasthenia gravis patients with topline results anticipated in 1H27 Enrollment ongoing for Phase 3 UPSTREAM SjD of telitacicept in primary Sjögren's disease Pro-forma cash and investment balance of $514.5 million expected to provide runway into early 2029 BOSTON, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today reported financial results for the second quarter ended June 30, 2026, and provided a corporate update. “We continued to make meaningful progress in 2026 with telitacicept receiving its fourth and fifth commercial approvals in China for the treatment of Sjögren's disease and IgA nephropathy and its Phase 3 TELIGAN trial in IgA nephropathy being featured in The New England Journal of Medicine.

GlobeNewsWire

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, on August 1, 2026, the Compensation Committee of the Board of Directors granted stock options to purchase an aggregate of 32,550 shares of Vor Bio's common stock and restricted stock units ("RSUs") representing the right to receive an aggregate of 6,900 shares of Vor Bio's common stock to 5 newly hired employees.

Globe News Wire

Sorpresas de ganancias

Período	Estimado	Real	Sorpresa
2026-05-13	-0.75	-0.73	0.02
2026-03-30	-1.14	44.5	45.64
2025-11-13	-3.06	-3.33	-0.27
2025-08-12	-11.4	-43.6	-32.2
2025-05-14	-0.25	-0.26	-0.01
2025-03-20	-0.34	-0.44	-0.1
2024-11-07	-0.4	-0.4	0
2024-08-08	-0.41	-0.41	0
2024-05-09	-0.37	-0.45	-0.08
2024-03-20	-0.49	-0.39	0.1
2023-11-07	-0.46	-0.49	-0.03
2023-08-10	-0.42	-0.45	-0.03